Rocket Pharmaceuticals
RCKT
34 hedge funds and large institutions have $32.1M invested in Rocket Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 10 closing their positions.
352% more call options, than puts
Call options by funds: $104K | Put options by funds: $23K
102% more capital invested
Capital invested by funds: $15.9M → $32.1M (+$16.2M)
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
2.75% more ownership
Funds ownership: 8.26% → 11.01% (+2.7%)
0% more funds holding
Funds holding: 34 → 34 (0)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$3.22M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$2.48M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.42M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.24M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$896K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$877K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$747K |
| 3 |
Jennison Associates
New York
|
-$471K |
| 4 |
SAM
Senzar Asset Management
New York
|
-$359K |
| 5 |
Millennium Management
New York
|
-$359K |
RCKT Hedge Fund Activity: Q4 2017 in Review
34 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2017, worth a combined $32.1M — up 102% from $15.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RCKT positions and 10 closed out — a net gain of 1 holder — while 9 added to existing stakes and 10 trimmed.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $3.22M. The largest seller was GSA Capital Partners, cutting an estimated $877K.
- 34 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $32.1M of Rocket Pharmaceuticals stock for Q4 2017, up 102% quarter-over-quarter.
- 11 funds opened new Rocket Pharmaceuticals positions in Q4 2017 and 10 closed out, a net change of +1 holder.
- The largest Rocket Pharmaceuticals buyer in Q4 2017 was Ghost Tree Capital, an estimated $3.22M added.
- The largest Rocket Pharmaceuticals seller in Q4 2017 was GSA Capital Partners, an estimated $877K sold.
Based on aggregated 13F filings for Q4 2017.